

Article's title: DERIVATIVES OF PIPERAZINES AS POTENTIAL THERAPEUTIC AGENTS FOR ALZHEIMER'S DISEASE

Authors: Elena Popugaeva, Daria Chernyuk, Hua Zhang, Tatyana Y. Postnikova, Karina Pats, Elena Fedorova, Vladimir Poroikov, Aleksey V. Zaitsev, Ilya Bezprozvanny

Journal title: Molecular Pharmacology


Name of the supplemental file: Integrity product report

Product Report

Copyright 2015 - Prous Science. All rights reserved.

Query:

1 of 36

Entry Number 194656 Record Creation Date May 19, 1993 Last Updated Date Jun 02, 2013 CAS Registry No. 2999-10-2 Molecular Formula C16 H22 O5 Molecular Weight 294.3429 Highest Phase Preclinical Under Active Development No Link to Integrity	Chemical Structure  Hyp-1	
Chemical Name/Description 2,4 - Bis(3 - methylbutyryl)phloroglucinol 2,4 - Bis(3 - methylbutyryl) - 1,3,5 - trihydroxybenzene		
Code Name Hyp-1	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Agonists Leukotriene CysLT1 (LTD4) Antagonists Free Fatty Acid Receptor 1 (FFAR1; GPR40) Agonists Signal Transduction Modulators Prostanoid TP Antagonists Leukotriene Antagonists		Cellular Mechanism
Organization Piramal Life Sciences UCB Japan (Originator)	Therapeutic Group Antiallergy/Antiasthmatic Drugs Antiviral Drugs Type 2 Diabetes, Agents for	Condition Infection, viral Diabetes type 2 Asthma, allergic
Product Summary		


Update History (40 most recent)

Change Date	Change Type	Change Value
Jun 02, 2013	New Mechanism of Action	Signal Transduction Modulators
Oct 26, 2012	New Product Name	Hyp-1 (Code Name)
Oct 26, 2012	New Related Reference	Mol Pharmacol 2010, 77(3): 368
Oct 26, 2012	New Mechanism of Action	TRPC6 Agonists
Jan 15, 2009	Updated Highest Phase Field	Preclinical
Jan 15, 2009	New Mechanism of Action	Free Fatty Acid Receptor 1 (FFAR1; GPR40) Agonists
Jan 15, 2009	New Therapeutic Group	Type 2 Diabetes, Agents for
Jan 15, 2009	New Condition	Diabetes type 2
Jan 15, 2009	New Organization	Piramal Life Sciences
Jan 14, 2009	New Related Reference	Bioorg Med Chem Lett 2008, 18(24): 6357

Related Information - Records in other Knowledge Areas

Drugs & Biologics	0	Companies & Research Institutions	2
Literature	8	Targets & Pathways	4
Patents	3	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

2 of 36

Entry Number 278291 Record Creation Date Jun 05, 2002 Last Updated Date Jul 21, 2015 CAS Registry No. 11079-53-1 (free base) Molecular Formula C ₃₅ H ₅₂ O ₄ · C ₁₂ H ₂₃ N Molecular Weight 718.1027 Highest Phase Clinical Under Active Development No Link to Integrity		Chemical Structure  <p style="text-align: center;">Hyperforin-DCHA</p>	
Chemical Name/Description (1R,5R,7S,8R) - 4 - Hydroxy - 1 - isobutyryl - 8 - methyl - 3,5,7 - tris(3 - methyl - 2 - butenyl) - 8 - (4 - methyl - 3 - pentenyl)bicyclo[3.3.1]non - 3 - ene - 2,9 - dionedicyclohexylamine salt (1S,5S,6R,7S) - 4 - Hydroxy - 5 - isobutyryl - 6 - methyl - 1,3,7 - tris(3 - methyl - 2 - butenyl) - 6 - (4 - methyl - 3 - pentenyl)bicyclo[3.3.1]non - 3 - ene - 2,4,9 - trione dicyclohexylamine salt			
Code Name	Generic Name Hyperforin Hyperforin-DCHA	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source Hypericum perforatum (Whole plant);	
Molecular Mechanism 5-Lipoxygenase Inhibitors TRPC6 Agonists Signal Transduction Modulators Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors alpha-Secretase Activators		Cellular Mechanism	
Organization Schwabe (Originator) Universitaet Freiburg (Originator)	Therapeutic Group Atopic Dermatitis, Agents for Oncolytic Drugs Antidepressants	Condition Depression Dermatitis, atopic Cancer	
Product Summary			


Update History (40 most recent)

Change Date	Change Type	Change Value
Jul 21, 2015	New Related Reference	Arch Pharmacol Res 2015, 38(7): 1281
May 05, 2015	New Related Patent Family	Composition for treating postmenopausal syndrome
Apr 10, 2015	New Related Reference	J Clin Invest 2015, 125(4): 1388
Mar 11, 2015	New Related Reference	J Antimicrob Chemother 2015, 70(1): 322
Mar 07, 2015	New Related Reference	J Org Chem 2015, 80(3): 1735
Feb 07, 2015	New Related Reference	44th Annu Meet Soc Neurosci (November 15-19, Washington)

		2014, Abst 713.16
Aug 01, 2014	New Related Reference	Angew Chem Int Ed 2014, 53(26): 6701
Jul 12, 2014	New Related Patent Family	The composition containing a skin external preparation and an inclusion composite complex
Feb 06, 2014	New Related Reference	J Nat Prod 2013, 76(9): 1819
Jan 10, 2014	New Related Reference	Basic Clin Pharmacol Toxicol 2014, 114(1): 83
Oct 23, 2013	New Related Reference	10th Int ISSX Meet (September 30-October 3, Toronto) 2013, Abst P236
Sep 28, 2013	New Related Reference	61st Int Congr Annu Meet Soc Med Plant Nat Prod Res (September 1-5, Munster) 2013, Abst PJ14
Jul 24, 2013	New Related Reference	Synthesis (Stuttgart) 2013, 45(11)
Jun 28, 2013	New Related Reference	Chemistry (Weinheim) 2009, 15(40): 1047
Jun 28, 2013	New Related Reference	Drug Discov Today 2013, 18(11-12): 574
Jun 27, 2013	New Related Reference	Eur J Org Chem 2008, J(5): 925
Jun 25, 2013	New Related Reference	Chemistry (Weinheim) 2009, 15(40): 1047
Jun 14, 2013	New Related Reference	J Pharm Pharmacol 2013, 65(6): 907
Jun 02, 2013	New Mechanism of Action	Signal Transduction Modulators
Apr 13, 2013	New Related Reference	Tetrahedron Lett 2013, 54(15): 2022
Mar 24, 2013	New Related Reference	J Cereb Blood Flow Metab 2013, 33(2): 253
Mar 24, 2013	New Related Reference	Curr Cancer Drug Targets 2013, 13(1): 1
Feb 21, 2013	New Related Reference	J Pharm Pharmacol 2012, 64(12): 1770
Oct 26, 2012	New Related Reference	Mol Pharmacol 2010, 77(3): 368
Oct 24, 2012	New Mechanism of Action	TRPC6 Agonists
Oct 24, 2012	New Related Reference	Curr Pharm Biotechnol 2011, 12(1): 35
Aug 02, 2012	New Related Reference	Eur J Pharm Biopharm 2012, 81(2): 346
Feb 25, 2012	New Related Reference	Eur J Org Chem 2012, (3): 484
Jan 17, 2012	New Related Reference	J Neurochem 2011, 119(3): 555
Jan 11, 2012	New Related Reference	Neuropharmacology 2011, 61(8): 1321
Dec 03, 2011	New Related Reference	Int J Oncol 2012, 40(1): 269
Sep 30, 2011	New Related Reference	Int J Oncol 2011, 39(4): 965
Sep 09, 2011	New Related Reference	Inflamm Res 2011, 60: Abst P-600
Aug 13, 2011	New Related Reference	Planta Med 2010, 76(12): Abst P598
Jun 28, 2011	New Related Reference	Pharmacol Res 2011, 63(1): 37
Jun 21, 2011	New Related Reference	Planta Med 2010, 76(12): Abst P574
Jun 21, 2011	New Related Reference	Planta Med 2010, 76(12): Abst P591
Jun 17, 2011	New Related Patent Family	A method for extracting Hypericum perforatum, extractive and pharmacy use
Apr 27, 2011	New Related Reference	Planta Med 2010, 76(12): 1325
Jan 14, 2011	New Related Reference	Tetrahedron 2010, 66(33): 6569

Related Information - Records in other Knowledge Areas

Drugs & Biologics	4	Companies & Research Institutions	2
Literature	149	Targets & Pathways	5
Patents	8	Experimental Pharmacology	86
Disease Briefings	0	Pharmacokinetics/ Metabolism	42
Clinical Studies	0	Biomarkers	2
Organic Synthesis	9	Experimental Models	12


Entry Number	427853	Chemical Structure	
Record Creation Date	Feb 16, 2008	 <p style="text-align: center;">ACA</p>	
Last Updated Date	May 29, 2014		
CAS Registry No.			
Molecular Formula	C21 H23 N O3		
Molecular Weight	337.4122		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		Structure Entry Date	Feb 16, 2008
Chemical Name/Description			
2 - [[[(2E) - 3 - (4 - Pentylphenyl)prop - 2 - enoyl]amino]benzoic acid			
Code Name	Generic Name	Brand Name	
ACA			
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism		Cellular Mechanism	
Signal Transduction Modulators TRPM2 Antagonists TRPM8 (TRP-p8; CMR1) Antagonists Phospholipase A2 (PLA2) Inhibitors TRPC6 Antagonists			
Organization	Therapeutic Group	Condition	
EMD Chemicals Freie Universitaet Berlin Charite Universitaetsmedizin Berlin	Pharmacological Tools		
Product Summary			

Update History (40 most recent)

Change Date	Change Type	Change Value
May 29, 2014	New Related Reference	Exp Biol (April 26-30, San Diego) 2014, Abst 644.17
Jun 02, 2013	New Mechanism of Action	Signal Transduction Modulators
Oct 24, 2012	New Related Reference	Curr Pharm Biotechnol 2011, 12(1): 35
May 18, 2012	New Chemical Name	2-[[[(2E)-3-(4-Pentylphenyl)prop-2-enoyl]amino]benzoic acid
May 18, 2012	New Related Reference	Neurochem Res 2012, 37(2): 314
May 17, 2012	New Related Reference	Biochem Pharmacol 2012, 83(8): 1021
Dec 29, 2011	New Related Patent Family	ACA submicron emulsion for intravenous injection and preparation method and application thereof
Aug 06, 2011	New Organization	EMD Chemicals
Oct 21, 2010	New Related Reference	Naunyn-Schmied Arch Pharmacol 2009, 380(6): 497

Related Information - Records in other Knowledge Areas

Drugs & Biologics	0	Companies & Research Institutions	2
Literature	7	Targets & Pathways	4
Patents	1	Experimental Pharmacology	5
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

Entry Number 753180 Record Creation Date Nov 25, 2011 Last Updated Date Aug 01, 2015 CAS Registry No. Molecular Formula C21 H22 Cl N3 O Molecular Weight 367.872 Highest Phase Preclinical Under Active Development No Link to Integrity	Chemical Structure  SAR-7334 Structure Entry Date Nov 25, 2011	
Chemical Name/Description 4 - [2(R) - [3(R) - Aminopiperidin - 1 - yl] - 2,3 - dihydro - 1H - inden - 1(R) - yloxy] - 3 - chlorobenzonitrile		
Code Name SAR-7334	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Sanofi (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of	Condition Chronic obstructive pulmonary disease (COPD)
Product Summary		

Update History (40 most recent)


Change Date	Change Type	Change Value
Aug 01, 2015	New Related Reference	Drug Data Rep Abst 2015, 37(5)
May 13, 2015	Updated Highest Phase Field	Preclinical
May 13, 2015	New Product Name	SAR-7334 (Code Name)
May 13, 2015	New Related Reference	Br J Pharmacol 2015 Adv. Publication

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	4	Targets & Pathways	1
Patents	1	Experimental Pharmacology	0
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

5 of 36


Entry Number 753181 Record Creation Date Nov 25, 2011 CAS Registry No. Molecular Formula C21 H22 N4 O3 Molecular Weight 378.4244 Highest Phase Biological Testing Under Active Development No	Chemical Structure
--	---------------------------

Development Link to Integrity		 <p style="text-align: center;">753181</p>	
		Structure Entry Date Nov 25, 2011	
Chemical Name/Description 4 - [2(R) - [3(R) - Aminopiperidin - 1 - yl] - 2,3 - dihydro - 1H - inden - 1(R) - yloxy] - 3 - nitrobenzonitrile			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization Sanofi (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Non-Opioid Analgesics Treatment of Disorders of the Coronary Arteries and Atherosclerosis Oncolytic Drugs Renal Failure, Agents for Treatment of Peripheral Obstructive Vascular Disease	Condition Renal failure Pain Chronic obstructive pulmonary disease (COPD) Coronary artery disease Vascular disease, peripheral obstructive Cancer	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	0
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

6 of 36

Entry Number 768057 Record Creation Date Apr 11, 2012 Last Updated Date Oct 04, 2013 CAS Registry No. Molecular Formula C20 H19 N3 O2 S Molecular Weight 365.449 Highest Phase Preclinical Under Active Development No Link to Integrity	Chemical Structure  <p style="text-align: center;">768057</p> Structure Entry Date Apr 11, 2012
Chemical Name/Description	

3,4 - Dihydroisoquinolin - 2(1H) - yl[2 - [(4 - methoxyphenyl)amino] - 1,3 - thiazol - 4 - yl]methanone		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists TRPC3 Antagonists		Cellular Mechanism
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure
Product Summary		


Update History (40 most recent)

Change Date	Change Type	Change Value
Oct 04, 2013	Updated Highest Phase Field	Preclinical
Oct 04, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	3	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	8
Disease Briefings	0	Pharmacokinetics/ Metabolism	4
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

7 of 36

Entry Number	768061	Chemical Structure	
Record Creation Date	Apr 11, 2012	 <p>768061</p>	
Last Updated Date	Oct 04, 2013		
CAS Registry No.			
Molecular Formula	C22 H21 N3 O3 S		
Molecular Weight	407.485		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		Structure Entry Date	Apr 11, 2012
Chemical Name/Description [2 - (1,3 - Benzodioxol - 5 - yl)amino] - 5 - methyl - 1,3 - thiazol - 4 - yl] (1 - methyl - 3,4 - dihydroisoquinolin - 2(1H) - yl)methanone			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists		Cellular Mechanism	
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure	
Product Summary			

Update History (40 most recent)


Change Date	Change Type	Change Value
-------------	-------------	--------------

Oct 04, 2013	New Mechanism of Action	TRPC6 Antagonists
Oct 04, 2013	New Mechanism of Action	TRPC3 Antagonists
Sep 19, 2013	Updated Highest Phase Field	Preclinical
Sep 19, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	6
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

8 of 36

Entry Number 768069 Record Creation Date Apr 11, 2012 Last Updated Date Oct 04, 2013 CAS Registry No. Molecular Formula C18 H23 N3 O S Molecular Weight 329.46 Highest Phase Preclinical Under Active Development No Link to Integrity	Chemical Structure  768069 Structure Entry Date Apr 11, 2012	
Chemical Name/Description (2,3 - Dimethylpiperidin - 1 - yl)[2 - [(4 - methylphenyl)amino] - 1,3 - thiazol - 4 - yl]methanone		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists TRPC3 Antagonists		Cellular Mechanism
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure
Product Summary		

Update History (40 most recent)


Change Date	Change Type	Change Value
Oct 04, 2013	New Mechanism of Action	TRPC6 Antagonists
Sep 19, 2013	Updated Highest Phase Field	Preclinical
Sep 19, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	6	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	7
Disease Briefings	0	Pharmacokinetics/ Metabolism	5
Clinical Studies	0	Biomarkers	0

Organic Synthesis	0	Experimental Models	0
-------------------	---	---------------------	---

9 of 36

Entry Number 768070 Record Creation Date Apr 11, 2012 Last Updated Date Oct 04, 2013 CAS Registry No. Molecular Formula C18 H19 Cl F N3 O3 S Molecular Weight 411.878 Highest Phase Preclinical Under Active Development No Link to Integrity	Chemical Structure  768070 Structure Entry Date Apr 11, 2012	
Chemical Name/Description [5 - Chloro - 2 - [(6 - fluoro - 1,3 - benzodioxol - 5 - yl)amino] - 1,3 - thiazol - 4 - yl](2,3 - dimethylpiperidin - 1 - yl)methanone		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists TRPC3 Antagonists		Cellular Mechanism
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure
Product Summary		


Update History (40 most recent)

Change Date	Change Type	Change Value
Oct 04, 2013	New Mechanism of Action	TRPC6 Antagonists
Oct 04, 2013	New Mechanism of Action	TRPC3 Antagonists
Sep 19, 2013	Updated Highest Phase Field	Preclinical
Sep 19, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	6
Disease Briefings	0	Pharmacokinetics/ Metabolism	5
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

10 of 36

Entry Number 768075 Record Creation Date Apr 11, 2012 Last Updated Date Oct 04, 2013 CAS Registry No. Molecular Formula C18 H21 N3 O3 S Molecular Weight 359.443	Chemical Structure  768075
---	---

Highest Phase	Preclinical	Structure Entry Date	Apr 11, 2012
Under Active Development	No		
Link to Integrity			
Chemical Name/Description [2 - (1,3 - Benzodioxol - 5 - ylamino) - 1,3 - thiazol - 4 - yl](2,3 - dimethylpiperidin - 1 - yl)methanone			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists		Cellular Mechanism	
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure	
Product Summary			


Update History (40 most recent)

Change Date	Change Type	Change Value
Oct 04, 2013	New Mechanism of Action	TRPC6 Antagonists
Oct 04, 2013	New Mechanism of Action	TRPC3 Antagonists
Sep 19, 2013	Updated Highest Phase Field	Preclinical
Sep 19, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	6
Disease Briefings	0	Pharmacokinetics/ Metabolism	5
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0


11 of 36

Entry Number	768079	Chemical Structure	
Record Creation Date	Apr 11, 2012		
CAS Registry No.			768079
Molecular Formula	C17 H21 N3 O2 S	Structure Entry Date	Apr 11, 2012
Molecular Weight	331.433		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description [2 - [(3 - Methoxyphenyl)amino] - 1,3 - thiazol - 4 - yl](4 - methylpiperidin - 1 - yl)methanone			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure	

Product Summary**Related Information - Records in other Knowledge Areas**

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	3
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

12 of 36

Entry Number	768080	Chemical Structure	
Record Creation Date	Apr 11, 2012		
Last Updated Date	Oct 04, 2013		
CAS Registry No.			
Molecular Formula	C16 H18 Cl N3 O S		
Molecular Weight	335.852		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		Structure Entry Date	Apr 11, 2012
Chemical Name/Description [2 - [(3 - Chlorophenyl)amino] - 1,3 - thiazol - 4 - yl](4 - methylpiperidin - 1 - yl)methanone			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists	Cellular Mechanism		
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure	
Product Summary			

Update History (40 most recent)

Change Date	Change Type	Change Value
Oct 04, 2013	New Mechanism of Action	TRPC3 Antagonists
Oct 04, 2013	New Related Reference	Bioorg Med Chem Lett 2013, 23(17): 4979

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	1	Experimental Pharmacology	5
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

13 of 36

Entry Number	785045	Chemical Structure	
Record Creation Date	Sep 07, 2012	GSK-2833503A	
Last Updated Date	Feb 22, 2014		
CAS Registry No.			
Molecular Formula			
Molecular Weight			
Highest Phase	Preclinical		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
Code Name	Generic Name	Brand Name	
GSK-2833503A			
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism		Cellular Mechanism	
TRPC3 Antagonists TRPC6 Antagonists			
Organization	Therapeutic Group	Condition	
GlaxoSmithKline (Originator)	Cardiovascular Diseases (Not Specified)	Other cardiovascular disorders	
Product Summary			

Update History (40 most recent)

Change Date	Change Type	Change Value
Feb 22, 2014	New Related Reference	Proc Natl Acad Sci USA 2014, 111(4): 1551

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

14 of 36

Entry Number	785046	Chemical Structure	
Record Creation Date	Sep 07, 2012	GSK-2332255B	
Last Updated Date	Feb 22, 2014		
CAS Registry No.			
Molecular Formula			
Molecular Weight			
Highest Phase	Preclinical		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
Code Name	Generic Name	Brand Name	
GSK-2332255B			
Product Category	Prescription/ Indication Type	Natural Source	

Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists		Cellular Mechanism
Organization GlaxoSmithKline (Originator)	Therapeutic Group Cardiovascular Diseases (Not Specified)	Condition Other cardiovascular disorders
Product Summary		


Update History (40 most recent)

Change Date	Change Type	Change Value
Feb 22, 2014	New Related Reference	Proc Natl Acad Sci USA 2014, 111(4): 1551

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	2	Targets & Pathways	3
Patents	0	Experimental Pharmacology	3
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

15 of 36

Entry Number 791223 Record Creation Date Oct 24, 2012 Last Updated Date Jul 06, 2013 CAS Registry No. Molecular Formula C15 H18 N2 Molecular Weight 226.3168 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  791223 Structure Entry Date Oct 24, 2012	
Chemical Name/Description 4,6 - Dimethyl - 2 - (pyrrolidin - 1 - yl)quinoline		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists TRPC4 Antagonists		Cellular Mechanism
Organization Johns Hopkins University School Medicine Univ Texas Health Sci Center at Houston Vanderbilt University	Therapeutic Group Pharmacological Tools	Condition
Product Summary		

Update History (40 most recent)


Change Date	Change Type	Change Value
Jul 06, 2013	New Related Patent Family	TRPC4 modulators for use in the treatment or prevention of

		pain
--	--	------

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	3
Literature	1	Targets & Pathways	2
Patents	1	Experimental Pharmacology	3
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

16 of 36


Entry Number 791224 Record Creation Date Oct 24, 2012 Last Updated Date Jul 06, 2013 CAS Registry No. Molecular Formula C16 H20 N2 Molecular Weight 240.3434 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  791224 Structure Entry Date Oct 24, 2012	
Chemical Name/Description 6 - Ethyl - 4 - methyl - 2 - (pyrrolidin - 1 - yl)quinoline		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC4 Antagonists TRPC6 Antagonists		Cellular Mechanism
Organization Johns Hopkins University School of Medicine Univ Texas Health Sci Center at Houston Vanderbilt University	Therapeutic Group Pharmacological Tools	Condition
Product Summary		

Update History (40 most recent)

Change Date	Change Type	Change Value
Jul 06, 2013	New Related Patent Family	TRPC4 modulators for use in the treatment or prevention of pain


Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	3
Literature	1	Targets & Pathways	2
Patents	1	Experimental Pharmacology	3
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

Entry Number	791565	Chemical Structure	
Record Creation Date	Oct 26, 2012	 <p>Hyp-5</p>	
CAS Registry No.			
Molecular Formula	C18 H26 O5		
Molecular Weight	322.396		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
1,1' - (2,4,6 - Trihydroxybenzene - 1,3 - diyl)bis(4 - methylpentan - 1 - one)			
Code Name	Hyp-5	Generic Name	Brand Name
Product Category		Prescription/ Indication Type	Natural Source
Molecular Mechanism		Cellular Mechanism	
TRPC6 Agonists			
Organization	Therapeutic Group	Condition	
Schwabe (Originator) Universitaet Heidelberg (Originator) Ss Cyril and Methodius University (Originator) Eberhard Karls-Universitaet Tuebingen (Originator) Charite Universitaetsmedizin Berlin (Originator) Johann Wolfgang Goethe Universitaet (Originator)	Cognition Disorders, Treatment of	Cognitive disorders	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	6
Literature	1	Targets & Pathways	1
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

Entry Number	791566	Chemical Structure	
Record Creation Date	Oct 26, 2012	 <p>Hyp-9</p>	
CAS Registry No.			
Molecular Formula	C18 H26 O5		
Molecular Weight	322.396		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
1,1' - (2,4,6 - Trihydroxybenzene - 1,3 - diyl)dihexan - 1 - one			
Code Name		Generic Name	Brand Name

Hyp-9		
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Agonists		Cellular Mechanism
Organization Ss Cyril and Methodius University (Originator) Universitaet Heidelberg (Originator) Schwabe (Originator) Eberhard Karls-Universitaet Tuebingen (Originator) Johann Wolfgang Goethe Universitaet (Originator) Charite Universitaetsmedizin Berlin (Originator)	Therapeutic Group Cognition Disorders, Treatment of	Condition Cognitive disorders
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	6
Literature	1	Targets & Pathways	1
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

19 of 36

Entry Number	818867	Chemical Structure	
Record Creation Date	Sep 19, 2013	GSK-1702934A	
Last Updated Date	Jun 23, 2015		
CAS Registry No.			
Molecular Formula			
Molecular Weight			
Highest Phase	Preclinical		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
Code Name	GSK-1702934A	Generic Name	Brand Name
Product Category		Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Agonists TRPC6 Antagonists		Cellular Mechanism	
Organization	GlaxoSmithKline (Originator)	Therapeutic Group	Condition
		Cardiovascular Diseases (Not Specified)	Cardiovascular Disorders
Product Summary			

Update History (40 most recent)

Change Date	Change Type	Change Value
-------------	-------------	--------------

Jun 23, 2015	New Related Reference	Cardiovasc Res 2015, 106(1): 163
--------------	-----------------------	----------------------------------

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	3	Targets & Pathways	1
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

20 of 36

Entry Number	818869	Chemical Structure	
Record Creation Date	Sep 19, 2013	GSK-417651A	
CAS Registry No.			
Molecular Formula			
Molecular Weight			
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description			
Code Name	GSK-417651A	Generic Name	Brand Name
Product Category		Prescription/ Indication Type	Natural Source
Molecular Mechanism		Cellular Mechanism	
TRPC6 Antagonists TRPC3 Antagonists			
Organization	GlaxoSmithKline (Originator)	Therapeutic Group	Condition
		Cardiovascular Diseases (Not Specified)	Cardiovascular Disorders
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	3
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

21 of 36


Entry Number	818872	Chemical Structure	
Record Creation Date	Sep 19, 2013	GSK-2293017A	
CAS Registry No.			
Molecular Formula			
Molecular Weight			
Highest Phase	Preclinical		

Under Active Development	No	
Link to Integrity		
Chemical Name/Description		
Code Name GSK-2293017A	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists		Cellular Mechanism
Organization GlaxoSmithKline (Originator)	Therapeutic Group Cardiovascular Diseases (Not Specified)	Condition Cardiovascular Disorders
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	2	Companies & Research Institutions	1
Literature	1	Targets & Pathways	3
Patents	0	Experimental Pharmacology	2
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

22 of 36


Entry Number	825447	Chemical Structure	
Record Creation Date	Oct 04, 2013		
CAS Registry No.			
Molecular Formula	C18 H21 Cl F N3 O S	825447	
Molecular Weight	381.895	Structure Entry Date Oct 04, 2013	
Highest Phase	Preclinical		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description [2 - [(4 - Chloro - 2 - fluorophenyl)amino] - 5 - methyl - 1,3 - thiazol - 4 - yl][(2S,3S) - 2,3 - dimethylpiperidin - 1 - yl]methanone			
Code Name		Generic Name	Brand Name
Product Category		Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC3 Antagonists TRPC6 Antagonists		Cellular Mechanism	
Organization GlaxoSmithKline (Originator)	Therapeutic Group Heart Failure Therapy	Condition Heart failure	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	0	Companies & Research Institutions	1
Literature	1	Targets & Pathways	3
Patents	1	Experimental Pharmacology	2

Disease Briefings	0	Pharmacokinetics/ Metabolism	5
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0


23 of 36

Entry Number	830288	Chemical Structure	
Record Creation Date	Nov 29, 2013	 <p style="text-align: center;">830288</p>	
CAS Registry No.			
Molecular Formula	C18 H18 Cl F N2 O		
Molecular Weight	332.8		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		Structure Entry Date	Nov 29, 2013
Chemical Name/Description			
[4 - (5 - Chloro - 2 - methylphenyl)piperazin - 1 - yl](3 - fluorophenyl)methanone			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism		Cellular Mechanism	
TRPC6 Agonists			
Organization	Therapeutic Group	Condition	
Kyoto University (Originator) Sumitomo Dainippon Pharma (Originator)	Psychiatric Disorders (Not Specified) Neurodegenerative Diseases, Treatment of	Neurodegeneration Psychiatric Disorders	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	0	Companies & Research Institutions	2
Literature	0	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

24 of 36


Entry Number	838461	Chemical Structure	
Record Creation Date	Feb 08, 2014	 <p style="text-align: center;">838461</p>	
CAS Registry No.			
Molecular Formula	C16 H16 Cl N3 O . Cl H		
Molecular Weight	338.232		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		Structure Entry Date	Feb 08, 2014
Chemical Name/Description			
(2S) - N - Carbamimidoyl - 3 - (3 - chlorophenyl) - 2 - phenylpropanamide hydrochloride			
Code Name	Generic Name	Brand Name	

Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	9	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

25 of 36


Entry Number	838462	Chemical Structure	
Record Creation Date	Feb 08, 2014		
CAS Registry No.			
Molecular Formula	C16 H15 Cl F N3 O . Cl H		
Molecular Weight	356.222		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
		838462	Structure Entry Date Feb 08, 2014
Chemical Name/Description (±) - N - Carbamimidoyl - 3 - (4 - chloro - 3 - fluorophenyl) - 2 - phenylpropanamide hydrochloride			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0

Organic Synthesis	0	Experimental Models	0
-------------------	---	---------------------	---


26 of 36

Entry Number 838464 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C16 H16 F N3 O . Cl H Molecular Weight 321.777 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838464 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (2S) - N - Carbamimidoyl - 2 - (4 - fluorophenyl) - 3 - phenylpropanamide hydrochloride		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

27 of 36


Entry Number 838465 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C17 H16 F3 N3 O2 . Cl H Molecular Weight 387.784 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838465 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (±) - N - Carbamimidoyl - 2 - [3 - (trifluoromethoxy)phenyl]propanamide hydrochloride		
Code Name	Generic Name	Brand Name

Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

28 of 36


Entry Number 838466 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C ₁₆ H ₁₆ Cl N ₃ O · Cl H Molecular Weight 338.232 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838466 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (±) - N - Carbamimidoyl - 3 - (3 - chlorophenyl) - 2 - phenylpropanamide hydrochloride		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0

Organic Synthesis	0	Experimental Models	0
-------------------	---	---------------------	---


29 of 36

Entry Number 838468 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C16 H16 Cl N3 O . Cl H Molecular Weight 338.232 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838468 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (±) - N - Carbamimidoyl - 3 - (4 - chlorophenyl) - 2 - phenylpropanamide hydrochloride		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	2	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

30 of 36


Entry Number 838469 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C16 H16 F N3 O . Cl H Molecular Weight 321.777 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838469 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (2S) - N - Carbamimidoyl - 3 - (3 - fluorophenyl) - 2 - phenylpropanamide hydrochloride		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source

Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation	
Product Summary			

Related Information - Records in other Knowledge Areas


Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

31 of 36

Entry Number 838470 Record Creation Date Feb 08, 2014 CAS Registry No. Molecular Formula C16 H16 Cl N3 O . Cl H Molecular Weight 338.232 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  838470 Structure Entry Date Feb 08, 2014	
Chemical Name/Description (±) - N - Carbamimidoyl - 2 - (3 - chlorophenyl) - 3 - phenylpropanamide hydrochloride		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		


Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

Entry Number	838471	Chemical Structure	
Record Creation Date	Feb 08, 2014	 <p style="text-align: center;">838471</p>	
CAS Registry No.			
Molecular Formula	C17 H19 N3 O . Cl H		
Molecular Weight	317.813		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description (2R,3R) - N - Carbamimidoyl - 2,3 - diphenylbutanamide hydrochloride			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0


Entry Number	838473	Chemical Structure	
Record Creation Date	Feb 08, 2014	 <p style="text-align: center;">838473</p>	
CAS Registry No.			
Molecular Formula	C16 H16 Cl N3 O . Cl H		
Molecular Weight	338.232		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity			
Chemical Name/Description (2S) - N - Carbamimidoyl - 3 - (4 - chlorophenyl) - 2 - phenylpropanamide hydrochloride			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	

Organization Glenmark Pharmaceuticals (Originator)	Therapeutic Group Chronic Obstructive Pulmonary Diseases (COPD), Treatment of Asthma Therapy Non-Opioid Analgesics Inflammation, Treatment of	Condition Pain Chronic obstructive pulmonary disease (COPD) Asthma Inflammation
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	2	Companies & Research Institutions	1
Literature	1	Targets & Pathways	1
Patents	1	Experimental Pharmacology	1
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

34 of 36

Entry Number	855096	Chemical Structure	
Record Creation Date	Jul 16, 2014		
Last Updated Date	May 27, 2015		
CAS Registry No.			
Molecular Formula	C22 H25 F N4 O3		
Molecular Weight	412.4573		
Highest Phase	Biological Testing		
Under Active Development	No		
Link to Integrity		855096	
		Structure Entry Date	Jul 16, 2014
Chemical Name/Description Ethyl 4 - [3 - (4 - fluorophenyl) - 7 - hydroxy - 2 - methylpyrazolo[1,5 - a]pyrimidin - 5 - yl] - 4 - methylpiperidine - 1 - carboxylate			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Antagonists		Cellular Mechanism	
Organization Wuhan University (Originator) Kunming Institute of Botany (Originator)	Therapeutic Group Treatment of Renal Diseases Cardiovascular Diseases (Not Specified)	Condition Hypertrophy, cardiac Glomerular disorders	
Product Summary			


Update History (40 most recent)

Change Date	Change Type	Change Value
May 27, 2015	New / Updated Structure	New / Updated Structure
May 27, 2015	New Chemical Name	Ethyl 4-[3-(4-fluorophenyl)-7-hydroxy-2-methylpyrazolo[1,5-a]pyrimidin-5-yl]-4-methylpiperidine-1-carboxylate
May 26, 2015	New Related Patent Family	One a pyrazolo[1 5-a]pyridine derivate and its anti-tumor application

Related Information - Records in other Knowledge Areas

Drugs & Biologics	0	Companies & Research Institutions	2
Literature	0	Targets & Pathways	1
Patents	2	Experimental Pharmacology	0
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

35 of 36


Entry Number 871099 Record Creation Date Mar 24, 2015 CAS Registry No. Molecular Formula C ₂₀ H ₂₄ Cl N ₃ O . C ₂ H ₃ F ₃ O ₂ Molecular Weight 471.9 Highest Phase Biological Testing Under Active Development No Link to Integrity	Chemical Structure  871099 Structure Entry Date Mar 24, 2015	
Chemical Name/Description N - (2 - Chlorophenyl) - 2 - [4 - (2,3 - dimethylphenyl)piperazin - 1 - yl]acetamide trifluoroacetate		
Code Name	Generic Name	Brand Name
Product Category	Prescription/ Indication Type	Natural Source
Molecular Mechanism TRPC6 Agonists TRPC3 Agonists		Cellular Mechanism
Organization Sumitomo Dainippon Pharma (Originator)	Therapeutic Group Psychiatric Disorders (Not Specified) Neurodegenerative Diseases, Treatment of	Condition Neurodegeneration Psychiatric Disorders
Product Summary		

Related Information - Records in other Knowledge Areas

Drugs & Biologics	2	Companies & Research Institutions	1
Literature	0	Targets & Pathways	3
Patents	1	Experimental Pharmacology	0
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0

36 of 36

Entry Number 880395 Record Creation Date Mar 24, 2015 CAS Registry No. Molecular Formula C ₂₀ H ₂₄ F ₃ N ₃ O . C ₂ H ₃ F ₃ O ₂ Molecular Weight 455.4458	Chemical Structure
---	---------------------------

Highest Phase Under Active Development Link to Integrity	Biological Testing No	 <p>880395</p>	
Chemical Name/Description			
2 - [4 - (2,3 - Dimethylphenyl)piperazin - 1 - yl] - N - (2 - fluorophenyl)acetamide trifluoroacetate			
Code Name	Generic Name	Brand Name	
Product Category	Prescription/ Indication Type	Natural Source	
Molecular Mechanism TRPC6 Agonists TRPC3 Agonists		Cellular Mechanism	
Organization Sumitomo Dainippon Pharma (Originator)	Therapeutic Group Psychiatric Disorders (Not Specified) Neurodegenerative Diseases, Treatment of	Condition Neurodegeneration Psychiatric Disorders	
Product Summary			

Related Information - Records in other Knowledge Areas

Drugs & Biologics	1	Companies & Research Institutions	1
Literature	0	Targets & Pathways	3
Patents	1	Experimental Pharmacology	0
Disease Briefings	0	Pharmacokinetics/ Metabolism	0
Clinical Studies	0	Biomarkers	0
Organic Synthesis	0	Experimental Models	0